A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs NGM 282 (Primary)
- Indications Primary sclerosing cholangitis
- Focus Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 13 Sep 2017 Status changed from active, no longer recruiting to completed.
- 31 Aug 2017 This trial has been completed in Netherlands , according to European Clinical Trials Database.
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.